Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has issued an update.
TempraMed Technologies Ltd. has signed an exclusive distribution agreement with Guri A.A.O., a leading distributor in Israel, to market and sell its full product line across the retail market in Israel. This strategic move marks a significant step in TempraMed’s shift from an online B2C model to large-scale retail pharmacy networks and B2B medical payers, aiming to improve global access and reduce patient acquisition costs. The partnership with Guri, which has extensive reach in Israel’s retail sector, is expected to enhance TempraMed’s market presence and support its global expansion strategy, targeting Europe, the Middle East, North America, and Asia. This agreement is anticipated to set a new standard for temperature-safe medication storage, benefiting patients who rely on such therapies.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. operates in the healthcare industry, focusing on temperature-control solutions for medications. The company is known for its innovative products that ensure the safe storage of temperature-sensitive medications, catering to a market that includes injectables, biologics, fertility medications, GLP-1 therapies, and insulin. TempraMed is expanding its reach globally, aiming to integrate its solutions into standard care practices.
Average Trading Volume: 6,194
Find detailed analytics on VIVI stock on TipRanks’ Stock Analysis page.